Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Eli Lilly anticipates full-year worldwide revenue of approximately $45.0 billion in 2024, reflecting a 32% year-over-year growth but falling slightly below the consensus estimate of $45.49 billion.